Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOLIXIR vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a xanthine derivative that acts as a competitive nonselective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, and as an antagonist at adenosine receptors (A1 and A2 subtypes), leading to bronchodilation, anti-inflammatory effects, and stimulation of respiratory drive.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
Oral: 200-400 mg every 6 hours (maximum 1600 mg/day) as sustained-release tablets or liquid. Inhalation: Not applicable.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life is 3–5 hours in adults (nonsmokers), but prolonged to 6–8 hours in neonates, elderly, and patients with hepatic cirrhosis or heart failure. Smoking (tobacco or marijuana) reduces half-life to 1–2 hours due to enzyme induction.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Hepatic metabolism via CYP1A2, CYP2E1, and CYP3A4. Approximately 10% excreted unchanged in urine.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal excretion of unchanged drug accounts for approximately 10% of elimination; the remainder is hepatically metabolized, with 80% excreted in urine as metabolites (1-methyluric acid and 3-methylxanthine) and less than 10% in feces.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Approximately 40% bound to albumin (primarily), with some binding to alpha-1-acid glycoprotein; binding is reduced in neonates and patients with hypoalbuminemia.
Approximately 70% bound to plasma proteins, primarily albumin.
0.3–0.7 L/kg; approximates total body water. Higher Vd in neonates (0.8 L/kg) due to increased extracellular fluid. Clinically, loading dose calculation uses Vd = 0.5 L/kg.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral immediate-release: 96–100% (virtually complete); sustained-release formulations: 80–100% (dependent on formulation and food effects).
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce dose by 50% and increase interval to every 12 hours. For GFR <10 m L/min: give 200 mg every 12-24 hours.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh A: no change. Child-Pugh B: reduce dose by 50% (maximum 800 mg/day). Child-Pugh C: reduce dose by 75% (maximum 400 mg/day) or increase interval to every 12-24 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Oral: Initial 5 mg/kg/dose every 6 hours; titrate to target serum concentration of 5-15 mcg/m L. Maximum: 20 mg/kg/day or 800 mg/day, whichever lower.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Start at lowest adult dose (200 mg every 6 hours) and monitor serum levels; decreased clearance may necessitate lower maintenance doses. Maximum daily dose 800 mg.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA black box warning.
None.
Narrow therapeutic index; serum levels should be monitored to avoid toxicity,Risk of seizures, arrhythmias, and death at high concentrations,Caution in patients with hepatic impairment, congestive heart failure, pulmonary edema, or fever,Potential for drug interactions with CYP1A2 inhibitors/inducers
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component of the formulation,Pre-existing cardiac arrhythmias (especially tachyarrhythmias)
Hypersensitivity to theophylline or any component of the formulation.
High-fat meals may alter theophylline absorption, leading to variable serum concentrations. Avoid excessive intake of caffeine-containing foods and beverages (e.g., coffee, tea, cola, chocolate) as they can potentiate stimulant effects and increase risk of toxicity. Charcoal-broiled foods may increase theophylline clearance, reducing efficacy.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Theophylline (active ingredient in THEOLIXIR) is not a major human teratogen. First trimester: Limited data show no consistent association with major malformations. Second/Third trimesters: Fetal tachycardia and jitteriness may occur at maternal therapeutic levels; toxicity can cause neonatal irritability, vomiting, and apnea. Risk of preterm labor or low birth weight not established.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted into breast milk with M/P ratio approximately 0.6-0.7. Average infant dose ~1.5% of maternal weight-adjusted dose. Considered compatible with breastfeeding; observe infant for irritability or sleep disturbance, especially with maternal doses >800 mg/day or high serum levels.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Pregnancy increases clearance of theophylline by 30-70% due to enhanced hepatic metabolism and increased renal elimination. Dose adjustments may be required to maintain therapeutic levels; monitor serum concentrations and adjust accordingly, especially in the third trimester. Postpartum clearance returns to prepregnancy levels, requiring downward dose adjustment.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Theophylline (THEOLIXIR) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Levels >20 mcg/m L increase toxicity risk. Administer with food if GI upset occurs, but avoid high-fat meals as they may increase absorption variability. Use with caution in patients with cardiac dysfunction, seizures, or peptic ulcer disease. Monitor for drug interactions with macrolides, fluoroquinolones, and cimetidine which decrease clearance.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take this medication exactly as prescribed; do not skip doses or double up.,Do not crush or chew extended-release tablets; swallow whole.,Get your blood levels checked regularly as directed by your doctor.,Avoid consuming large amounts of caffeine (coffee, tea, soda, chocolate) as it may increase side effects like jitteriness or rapid heartbeat.,Inform your doctor if you experience nausea, vomiting, restlessness, insomnia, or rapid heartbeat.,Do not stop taking this medicine suddenly without consulting your doctor.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOLIXIR vs AEROLATE JR, answered by our medical review team.
THEOLIXIR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a competitive nonselective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, and as an antagonist at adenosine receptors (A1 and A2 subtypes), leading to bronchodilation, anti-inflammatory effects, and stimulation of respiratory drive.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOLIXIR and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOLIXIR is: Oral: 200-400 mg every 6 hours (maximum 1600 mg/day) as sustained-release tablets or liquid. Inhalation: Not applicable.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOLIXIR and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOLIXIR is classified as Category C. Theophylline (active ingredient in THEOLIXIR) is not a major human teratogen. First trimester: Limited data show no consistent association with major malformations. Second/Third tr. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.